On Tuesday, Gain Therapeutics Inc (NASDAQ: GANX) opened lower -3.48% from the last session, before settling in for the closing price of $3.16. Price fluctuations for GANX have ranged from $1.41 to $4.34 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -37.02%. Company’s average yearly earnings per share was noted 27.64% at the time writing. With a float of $37.07 million, this company’s outstanding shares have now reached $38.46 million.
Gain Therapeutics Inc (GANX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Gain Therapeutics Inc is 3.62%, while institutional ownership is 11.29%.
Gain Therapeutics Inc (GANX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.08 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.19) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.30% during the next five years compared to -37.02% drop over the previous five years of trading.
Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators
Check out the current performance indicators for Gain Therapeutics Inc (GANX). In the past quarter, the stock posted a quick ratio of 2.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Gain Therapeutics Inc (GANX)
The latest stats from [Gain Therapeutics Inc, GANX] show that its last 5-days average volume of 0.87 million was superior to 0.6 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 48.03%.
During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 55.36%, which indicates a significant increase from 41.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.46 in the past 14 days, which was higher than the 0.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.84, while its 200-day Moving Average is $2.07. Now, the first resistance to watch is $3.16. This is followed by the second major resistance level at $3.27. The third major resistance level sits at $3.35. If the price goes on to break the first support level at $2.97, it is likely to go to the next support level at $2.89. Assuming the price breaks the second support level, the third support level stands at $2.78.
Gain Therapeutics Inc (NASDAQ: GANX) Key Stats
There are currently 38,462K shares outstanding in the company with a market cap of 117.31 million. Presently, the company’s annual sales total 0 K according to its annual income of -20,410 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -5,280 K.
